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Abstract PF-05231023, a long-acting FGF21 analogue, is a
promising potential pharmacotherapy for the treatment of
obesity and associated comorbidities. Previous studies have
shown the potential of FGF21 and FGF21-like compounds to
decrease body weight in mice, non-human primates, and
humans; the precisemechanisms of action remain unclear. In
particular, there have been conflicting reports on the degree
to which FGF21-inducedweight loss in non-human primates
is attributable to a decrease in food intake versus an increase
in energy expenditure. Here, we present a semi-mechanistic
mathematical model of energy balance and body composi-
tion developed from similar work in mice. This model links
PF-05231023 administration andwashout to changes in food
intake, which in turn drives changes in body weight. The
model is calibrated to and compared with recently published
data from cynomolgus macaques treated with PF-05231023,
demonstrating its accuracy in describing pharmacotherapy-
induced weight loss in these animals. The results are con-
sistent with the hypothesis that PF-05231023 decreases body
weight in cynomolgus macaques solely by a reduction in
food intake, with no direct effect on energy expenditure.
Keywords FGF21  Non-human primate  Body weight 
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Introduction
Type 2 diabetes mellitus (T2DM) is a substantial and
growing global health burden [1, 2], and obesity is a major
contributing factor to the development of T2DM [3–6].
There is, therefore, a need for novel pharmacotherapies for
the treatment of obesity and its comorbidities. Since its
initial identification [7], fibroblast growth factor 21
(FGF21) has been shown to be a key hormonal regulator of
glucose metabolism and energy balance [8–11], repre-
senting a promising potential approach for the treatment of
obesity and T2DM. PF-05231023 is a long-acting FGF21
analogue that has been shown to decrease body weight and
improve glucose tolerance in rodents [12].
FGF21 is known to signal through the FGFR1c receptor
and its cofactor b-klotho [9, 13] and appears to have both
central and peripheral effects. In the periphery, adipose
tissue is believed to be the primary target tissue, with
adiponectin-mediated downstream effects in the liver
[14–16]. FGF21 may also act on the leptin axis [17–19]. In
the central nervous system (CNS), FGF21 may alter
metabolism by affecting circadian rhythm [20]. In mice
with CNS-specific knockout of b-klotho, FGF21 does not
cause weight loss [21].
In spite of these findings, there remains considerable
uncertainty regarding the FGF21 mechanism(s) of action
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in vivo [9]. In rodents, FGF21 has been observed to
decrease body weight by increasing energy expenditure
[12, 22–24]. In non-human primates (NHP), there are
conflicting results: while an FGF21 analog reduced both
body weight and food intake [8], a monoclonal antibody
targeting the FGFR1c/b-klotho complex reduced body
weight without significant changes in food intake [9]. Thus,
it is an open question as to whether, or to what extent,
FGF21-mediated changes in body weight are driven by
changes in food intake and/or energy expenditure in NHP.
As FGF21 mimetics proceed into the clinic [25, 26],
there is significant interest in understanding the in vivo
mechanism(s) responsible for the observed therapeutic
effects. In a recent study in non-human primates [26],
multiple doses of PF-05231023 were tested for efficacy in
reducing food intake and body weight in male cynomolgus
macaques. To help determine the relative roles of
decreased food intake and increased energy expenditure in
contributing to the observed dose-responsive decrease in
body weight, food intake was measured daily for each
animal and body weight was measured weekly.
Based upon similarities in percent body weight change
between pair-fed animals and the highest-dosed groups, it
appears that a direct effect of PF-05231023 to decrease
energy intake is sufficient to explain the observed decrease
in body weight in NHP. However, there are several con-
founding factors. The pair-fed arm of the study was com-
pleted two months after the initiation of the dosing arms, so
that temporal differences as well as differences in baseline
characteristics could play a confounding role. As with all
pair-feeding studies, subtle behavioral differences (e.g., a
stress response caused by perceived food insecurity) could
lead to an altered metabolic phenotype. In rats, changes in
body composition associated with weight loss induced by
caloric restriction appear to be distinct from changes in
body composition induced by pharmacotherapy [27]. In
NHP, food access insecurity has been linked to changes in
body mass deposition [28–30].
To address these potentially confounding factors in a rig-
orous manner, a semi-mechanistic mathematical model of
body weight regulation is proposed based upon energy bal-
ance principles. Similar models have been developed and
validated for use with data from mice [31, 32], rats [27], and
humans [33], including for pharmacotherapy intervention
[27, 34, 35]. PF-05231023 action is linked to changes in food
intake through an inferred PKPDmodel. The dose-responsive
link between PF-05231023 administration and a hypothesized
mechanism of action (in this case, food intake reduction) is
used to demonstrate the NHP data are consistent with the
hypothesis that PF-05231023 acts directly onlyvia a reduction
in food intake. By withholding one of the study groups from
the model calibration procedure, the predictive capability of
the model is assessed.
To our knowledge, this is the first demonstration of an
energy balance model to analyze weight loss data in NHP
in the presence of pharmacotherapy. The results demon-
strate both the flexibility of the proposed modeling
framework, as well as the power of mathematical modeling
as a tool to support biological understanding.
Methods
All animal studies were conducted in accordance with
animal care and use protocols approved by the Institutional
Animal Care and Use Committee (IACUC) of Pfizer, Inc.
All procedures performed on any animals were in accor-
dance with regulations and established guidelines and were
reviewed and approved by a Pfizer Institutional Animal
Care and Use Committee. All experiments within this
manuscript were undertaken to minimize animal suffering
during the experiment.
This study complied with all applicable sections of the
Final Rules of the Animal Welfare Act regulations (Code
of Federal Regulations, Title 9), the Public Health Service
Policy on Humane Care and Use of Laboratory Animals
from the Office of Laboratory Animal Welfare, and the
Guide for the Care and Use of Laboratory Animals from
the National Research Council. The protocol and any
amendments or procedures involving the care or use of
animals in this study were reviewed and approved by the
Testing Facility Institutional Animal Care and Use Com-
mittee before the initiation of such procedures. All animals
were monitored and routine physical checkups were con-
ducted by veterinarians of the Testing Facility throughout
the study period.
Study design
The study protocol has been described in detail previously
[26]. Here, key components are summarized that are rele-
vant to the present analysis.
Untreated spontaneously obese male cynomolgus
macaques were individually housed in stainless steel cages
described in the Guide for the Care and Use of Laboratory
Animals. Animals were chair-trained and acclimatized
(including to vehicle injections) for three weeks prior to
study start. Seven days prior to study start, 36 animals were
randomized into 6 groups based upon body weight and
fasting TG. Baseline animal characteristics are summarized
in Table 1.
Groups received intravenous injections twice per week
for four weeks of vehicle (2 mL) or PF-05231023 (0.1, 1.0,
or 10.0 mg/kg). Following the end of the four week treat-
ment period, the vehicle, 0.1, and 1.0 mg/kg groups began
receiving vehicle only. The 10.0 mg/kg group received
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either vehicle only, 5 mg/kg once weekly, or 5 mg/kg twice
weekly. The treatment groups are summarized in Table 2.
For this analysis, time zero coincides with the admin-
istration of the first dose. Thus, doses were administered at
0, 3, 7, 10, 14, 17, 21, 24, 28, 31, 35, 38, 42, and 45 days.
At each dose time, all animals received an injection, with
vehicle replacing PF-05231023 for animals not assigned to
active dosing.
Food intake data
Pelleted food was provided twice daily (morning and
evening) for a period of 30 minutes. Food weight was
measured before and after administration, with the dif-
ference (correcting for spillage) recorded as consumption.
The pelleted food consisted of 180 g/kg protein, 36 g/kg
fiber, 59 g/kg fat, 60 g/kg ash, 10.3 g/kg calcium, 7.8 g/kg
phosphorous, and 94.8 g/kg moisture, with the remaining
552.1 g/kg assumed to be carbohydrate. Animals were
also provided with 100 g of apple slices each day. Animals
deemed to be sick or otherwise in need of veterinary
intervention were occasionally given either a steamed
cake or rice cereal. In both cases, the weight (steamed
cake) or volume (rice cereal) was recorded. No veterinary
interventions were associated with PF-05231023 admin-
istration. All animals were given ad libitum access to fresh
drinking water for the duration of the study.
Energy content of food
The caloric density of fat is assumed to be 9 kcal/g; the
caloric densities of protein and carbohydrate are assumed
to be 4 kcal/g. All other nutrients are assumed to provide
negligible caloric content. Thus each gram of the pelleted
food consists of 2.2084 kcal of carbohydrates, 0.72 kcal of
protein, and 0.5310 kcal of fat, for a total caloric density of
3.4594 kcal/g. The caloric content of apples is assumed to
be 0.52 kcal/g [36]. The steamed cakes are assumed to be
90 % carb with no other caloric content, and thus have an
energy density of 3.6 kcal/g (4 kcal/g 9 90 %). The rice
cereal is assumed to have been mixed 1:1 (cereal:water)
and thus have an energy density of 0.51 kcal/mL [37].
Body weight data
Body weight for all animals was measured weekly prior to
the administration of the first dose for that week.
Table 1 Summary of baseline characteristics for each treatment group
Group 1 (n = 5) Group 2 (n = 6) Group 3 (n = 6) Group 4 (n = 6) Group 5 (n = 6) Group 6 (n = 6)
Age (yr) 13.8 ± 0.8 14.5 ± 0.5 14.0 ± 0.9 12.9 ± 1.1 13.1 ± 1.1 12.6 ± 1.3
BW0 (kg) 10.1 ± 0.9 9.9 ± 1.3 10.6 ± 1.0 10.4 ± 0.3 10.6 ± 0.8 11.0 ± 1.0
BMI (kg/m2) 51.4 ± 4.6 48.0 ± 5.5 51.3 ± 2.9 48.0 ± 0.9 54.0 ± 2.8 52.1 ± 3.4
CHOL (mg/dL) 94.5 ± 7.9 103.2 ± 7.4 94.7 ± 12.3 105.4 ± 6.8 99.8 ± 9.7 111.3 ± 10.5
TG (mg/dL) 104.2 ± 25.7 96.2 ± 22.3 177.8 ± 46.1 192.2 ± 48.6 119.3 ± 24.9 202.8 ± 85.2
GLU (mg/dL) 98.2 ± 11.8 86.4 ± 4.4 165.3 ± 29.4 113.6 ± 16.3 92.8 ± 15.1 79.7 ± 8.8
HDL (mg/dL) 44.8 ± 6.2 47.8 ± 4.3 42.5 ± 3.9 51.2 ± 6.5 47.4 ± 6.8 53.9 ± 7.7
LDL (mg/dL) 34.8 ± 7.9 41.4 ± 4.5 27.7 ± 7.0 29.1 ± 1.5 36.4 ± 3.6 33.8 ± 4.0
After the conclusion of the initial study, animals from Group 1 were pair-fed to the mean food intake of Groups 4–6
BMI body mass index; CHOL total cholesterol; TG plasma triglycerides; GLU plasma glucose; HDL plasma high-density lipoprotein; LDL
plasma low-density lipoprotein. All data are reported as mean ± SE
Table 2 Summary of treatment
for each group
Group Treatment description
Group 1 Vehicle during treatment and washout phases (control group)
Group 2 0.1 mpk PF-05231023 twice/wk; vehicle only during washout period
Group 3 1.0 mpk PF-05231023 twice/wk; vehicle only during washout period
Group 4 10.0 mpk PF-05231023 twice/wk; vehicle only during washout period
Group 5 10.0 mpk PF-05231023 twice/wk; 5 mpk PF-05231023 once/wk during washout period
Group 6 10.0 mpk PF-05231023 twice/wk; 5 mpk PF-05231023 twice/wk during washout period
After the conclusion of the initial study, animals from Group 1 were pair-fed to the daily mean food intake
of Groups 4–6
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Data analysis
Tominimize interindividual variation between study animals,
all data are averaged within each group. Certain animals
consumed all food administered during the baseline period,
and thus could not be considered to be consuming ad libitum.
Inclusion of these animals could lead to a biased analysis as a
result of differences in perception of food security among the
groups. Thus, these animals have been discarded from the
present analysis (1 animal each fromGroups1, 2 and4).As the
groups are still approximately balanced, this exclusion does
not diminish the findings of this analysis.
Each source of food intake (pelleted food, apples, steamed
cake, rice cereal) is converted to kilocalories and the total
caloric intake is computed for each animal for each day. Then
mean caloric intake is computed for each group for each day
of the study. Mean body weight data are computed for each
group for each measurement time. All data are reported as
mean ± standard error of the mean (SE).
Body weight model
Previous authors have developed a mathematical model of
body weight change in response to energy imbalance which
has been used to describe dynamic body weight regulation
in humans and mice [31, 32, 38]. For small changes in body
weight, this model can be written as a linear differential
equation describing changes in body weight (BW) in




¼ I  I0ð Þ   BW  BW0ð Þ; ð1Þ
where BW0 (g) is body weight at time t = 0 (days, d), I0
(kcal/d) is baseline energy intake (the intake rate at which
BW0 is maintained), q (kcal/g) is the approximate energy
density of metabolic tissue adjusted for the cost of mass
deposition, and e (kcal/g/d) is a constant of proportionality
relating body weight to energy expenditure. A detailed
derivation of this model is included in the Appendix.
Food intake model
Food intake is treated as a continuous variable and changes
in food intake are assumed to be driven entirely by
pharmacotherapy,
I ¼ IðtÞ ¼ ð1þ rÞI0f ðtÞ; ð2Þ
where the function f(t) is given by
f ðtÞ ¼ 1 ImaxCðtÞ
CðtÞ þ IC50 : ð3Þ
Here, Imax is the maximum inhibitory effect of treatment
and IC50 is the level of drug concentration C(t) at which
50 % inhibition is obtained. The term ð1þ rÞ represents
the tendency of untreated animals to gain body weight.
(The simplified body weight model has a steady state
BW ¼ BW0 when I ¼ I0, so the factor of 1þ r describes
any offset from this steady state.)
In the absence of a well understood pharmacokinetic
model, a ‘K-PD’ [39] model can be used instead. Such a
model replaces a mechanistic pharmacokinetic model with
the simplest functional form that reliably recapitulates the
observed effects of the drug. In order to describe the onset
and washout time for the current drug, each dose is
described by the Bateman function. That is, given doses at
times ftig, the effective concentration of the drug at the site









Here, Di is the dose (mg/kg) adminstered at time ti and H(t)
is the Heaviside function. The volume of distribution is
omited from the K-PD model, and it is assumed IC50 has
been non-dimensionalized to this unknown volume. The
sum, indexed by i, is taken over the administered doses for
each group (Table 2).
Model solution
For a given set of model parameters (see below) and given
the dosing times ftig and the administered doses fDig for
each group, Eqs. (2)–(4) are computed exactly. The func-
tion I(t) and the initial body weight BW0 are then used to
compute BWðtÞ by Eq. (1). For the pair-feeding experi-
ment, the food intake data are inserted directly into (1) as a
piece-wise constant function.
Because I is a continuous variable but actual food intake
is measured daily, Eq. (2) is integrated to compute total





All computer code was written in MATLAB 7.11.0 (Math-
works, Inc.). The integration of Eqs. (1) and (5) was com-
puted using the MATLAB routine ode15s, a multi-step
solver implementing a numerical differentiation formula. For
the pair-feeding experiment, Eq. (1) was integrated in dis-
crete one day intervals to avoid discontinuities associated
with the use of a piece-wise constant function for food intake.
Data fitting
Absent sufficient prior information, model parameters must
be inferred from the available data. As the model param-
eters are not directly observable, this inference can be
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accomplished indirectly using an ordinary least squares
(OLS) approach. Only data from Groups 1–5 are used to
estimate model parameters, with Group 6 used to test the
predictive capacity of the model. The body weight model
parameters q, , the food intake parameters I0 and r, and the
K-PD model parameters ka, ke, Imax, and IC50 must be
estimated. Additionally, it is assumed that each group may
have a distinct rate of baseline food intake, so that five
separate parameters I
j
0 must be estimated. All model
parameters are estimated simultaneously.
Define
h ¼ fI10 ; I20 ; I30 ; I40 ; I50 ; r; ka; ke; Imax; IC50; q; g
. Let I^
j
k represent the mean food intake measured for group
j on day k and let T
j
k ðhÞ represent the model solution
computed according to Eq. (5) for group j and given model






k  T jk ðhÞ
 2
: ð6Þ
Similarly, let ^BW jk represent the mean body weight mea-
sured for group j on day k and let BW jðhÞ represent the
model solution computed according to Eq. (1) for group j





^BW jk  BW jðtiÞ
 2
: ð7Þ
For both Eqs. (6) and (7), the sum is computed over all time
points at which the appropriate measurement was taken, and
for Groups 1–5 (including the pair-feeding data for Group 1).
The OLS parameter estimate is






Thus, both the FI and BW data are fit simultaneously. Here,
wFI ¼ 1 and wBW ¼ 0:012 to approximately balance the
relative contributions of the food intake and body weight
components in the total squared error. The minimization
(8) was computed by a trust-region algorithm as imple-
mented in the MATLAB routine lsqnonlin. All com-
ponents of the estimate h^OLS are uniquely determinable
from the available data (work not shown).
Results
The best-fit parameter values are summarized in Table 3.
Point estimates are computed without confidence intervals
as a result of uncertainty regarding a suitable statistical
model of the data (see below).
For two model parameters, nominal/theoretical values
can be computed (see the Appendix) and compared to their
OLS estimates. Interestingly, the estimates obtained using
the calibration data set are not consistent with the theo-
retical values (q ¼ 8:4 vs. estimated 4.81 kcal/g;  ¼ 0:05
vs. estimated 0.162 kcal/g/d). This is most likely due to the
fact that the theoretical values are consistent with changes
in body composition which occur over long periods of time
[38], but shorter term changes (e.g., alterations in fluid
balance, glycogen stores, and protein metabolism) may
alter these theoretical values. It is also possible that
assumptions regarding the contributions of various mech-
anisms to energy expenditure [Eq. (11) in the Appendix]
may be oversimplified. In spite of this potential short-
coming, there is no systematic modeling error between
groups in the calibration data (Fig. 1) and, because the
model parameters q and  are assumed to be the same for
all groups, there is no evidence of dose-responsive changes
in body composition or energy expenditure associated with
PF-05231023 treatment.
The model solution corresponding to the best-fit
parameter values is shown in comparison to the data in
Fig. 1. The energy balance model describes the mean effect
of PF-05231023 on food intake at all doses, including the
washout period. This supports both the appropriateness of
the K-PD framework as well as the dose-responsiveness of
the hypothesized direct effect of PF-05231023 in reducing
food intake. The modeled change in food intake leads to a
predicted change in body weight that is consistent with the
observed data at all measurement times, supporting the
hypothesis that PF-05231023 acts to reduce body weight by
decreasing food intake without directly altering energy
expenditure [26].
The model residuals appear random and approximately
normally distributed (Fig. 5 in the Appendix), as expected
if the mathematical model is correctly specified [40].
However, the model solution appears to miss fluctuations
in food intake that occur on a time scale shorter than one
week (Fig. 1). This observation is supported by a lag
residual plot (Fig. 2), demonstrating a statistically signifi-
cant correlation between the modeling error at consecutive
measurement times. This indicates that an ordinary least
squares statistical model may not be appropriate [41] and
confidence intervals for parameter estimates would be
misleading [42]. However, it is not believed that a mis-
specified statistical model has a meaningful impact on the
mean parameter estimates reported in Table 3 [42].
The discrepancy between the model and the data at time
scales shorter than 7 days is likely caused by the complex
pharmacology of PF-05231023, which has been hypothe-
sized to operate at two distinct time scales in mice [12].
While the simple K-PD framework used in this study
cannot represent such complex pharmacology, it does
J Pharmacokinet Pharmacodyn (2016) 43:411–425 415
123
accurately describe the mean change in food intake over
longer time periods for all doses in the calibration data set.
As such, the proposed model is sufficient to draw conclu-
sions regarding the relationship between PF-05231023,
food intake, energy expenditure, and body weight change.
To further test the accuracy of the proposed energy
balance model for NHP data following PF-05231023
treatment, the treatment protocol for Group 6 (10 mg/kg
twice/wk for 4 weeks, followed by 5 mg/kg twice/wk) was
simulated and compared to the collected data. Because data
for Group 6 was not used in the model calibration, this
provides a meaningful test of the accuracy of the model.
For the calibration data sets, the baseline rate of energy
intake, I0, was estimated for each group. The resulting
parameter estimates exhibit an approximtely linear rela-
tionship with baseline body weight (Fig. 3). Thus, I0 for
Group 6 could be extrapolated using the value of BW0 for
Group 6. This value was then used with the parameters
from Table 3 to simulate the mathematical model.
Though the resulting estimate of I0 for Group 6 is
slightly high, the simulation accurately estimates the mean
change in food intake for Group 6, as well as mean change
in body weight secondary to decreased food intake (Fig. 4).
As for the calibration data set, fluctuations in food intake
that occur on a time scale faster than 7 days are not well-
modeled by the K-PD framework. The model over-predicts
food intake during the first two weeks of treatment, but is
accurate for weeks 3 and 4. Interestingly, the model is
approximately constant during these earlier times, while
food intake slowly increases from day 14 to day 28. No
similar effect is observed in the calibration data, and the
cause of this phenomenon in the Group 6 data is unknown.
While the model does predict a slight increase in food
intake after dosing is changed to 5 mg/kg at day 28, the
change observed in the data is much larger. In spite of these
shortcomings, the model provides an accurate prediction of
mean food intake over the course of the experiment, and
accurately predicts the change in body weight associated
with the treatment. This is particularly true given the
degree of variability exhibited in the data for Group 6, as
seen in the magnitude of the error bars in Fig. 4 during the
washout period.
Discussion
Administration of PF-05231023 has been observed to be
associated with dose-responsive decreases in food intake
and body weight in NHP [26]. While pair-feeding data are
strongly suggestive that PF-05231023 acts primarily to
reduce food intake, the compound is known to cause
increases in energy expenditure in mice [12]; moreover,
there are conflicting reports regarding the effects on energy
balance of other compounds targeting the FGF21 axis
[8, 9]. While it is possible to measure energy expenditure
directly, these data can be noisy and difficult to collect, and
were not collected for this experiment. The present study is
the first to our knowledge to develop an energy balance
model for use in describing pharmacotherapy-induced
weight loss in non-human primates. This model is used to
analyze the degree to which decreases in food intake fol-
lowing treatment with PF-05231023 are responsible for the
observed decreases in body weight in cynomolgus
macaques.
The energy balance model linking food intake and
energy expenditure to a change in body weight was adapted
Table 3 Summary of model
parameters, nominal values, and
OLS estimates. For parameters
q and e, theoretical values can
be derived
Parameter Description Nominal value Estimated value Units
I10 Baseline intake, Group 1 – 446.6 kcal/d
I20 Baseline intake, Group 2 – 387.6 kcal/d
I30 Baseline intake, Group 3 – 511.8 kcal/d
I40 Baseline intake, Group 4 – 503.9 kcal/d
I50 Baseline intake, Group 5 – 501.9 kcal/d
r Overconsumption factor – 0.094 –
ka Absorption/onset rate – 2.03 d
-1
ke Elimination/offset rate – 0.26 d
-1
Imax Max inhibition of FI – 0.71 –
IC50 Concentration for 50 % inhibition – 1.49 mg/kg
q Mean whole-body energy density 8.4 4.81 kcal/g
e Energy expenditure coefficient 0.05 0.162 kcal/g/d
OLS estimates are obtained by fitting the parameters to the calibration data set according to Eq. (8).
Because the K-PD framework is used to represent the onset and washout of PF-05231023, it is assumed that
the parameter IC50 has been non-dimensionalized to the volume of distribution of the active metabolite at
the site of action
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from a similar model originally developed for C57BL/6
mice [32]; comparable models have been used to describe
dynamic body weight changes in humans [33] and rats
[27]. These models have been shown to accurately describe
changes in body weight and body composition following
changes in food intake, and have even been used to
describe and analyze pharmacotherapy-induced weight loss
in mice [34] and humans [35]. However, it is possible that
the broader metabolic effects of pharmacotherapy-induced
weight loss are different from those associated with caloric
restriction [27]. Thus pair-feeding data alone may not be
sufficient to draw conclusions regarding the contributions
of energy intake and energy expenditure to decreased body
weight.
Here, a mathematical framework is established that
describes changes in body weight associated with both
PF-05231023 treatment and caloric restriction (pair-
feeding) simultaneously. The only direct effect of PF-
05231023 is assumed to be a reduction in food intake. The
mathematical model does permit energy expenditure to
change as a result of weight loss (i.e., because of the
decrease in metabolically active body mass), but such
changes occur identically in control, pair-fed, and
actively-dosed animals. Thus these changes in energy
expenditure depend only on existing (i.e., non-pharma-
cological) physiological mechanisms and are not associ-
ated with a direct response to treatment. This modeling
framework accurately describes average food intake for
all doses. The model also accurately describes changes in
body weight for all doses, including for the pair-feeding
arm of the current study. Thus any change in energy
expenditure directly attributable to drug treatment must be
within the modeling error, which is very small. As such,
the model supports the hypothesis that PF-05231023 acts
to reduce body weight in NHP strictly via reduction of
food intake. The dose-responsiveness of this effect (as
inferred via the K-PD formulation) further supports the
hypothesis. Because the calibrated model is able to
describe the rebound in food intake and body weight
during the washout period, the reductions in food intake
associated with PF-05231023 appear to be predominantly
PK-driven.
Two of the model parameters inferred from the data, q
and e, can be compared to theoretical values. Interestingly,
the values inferred differ significantly from the theoretical
values (Table 3). These parameters represent, respectively,
the average whole-body energy density (kcal/g) and the
energy expenditure per unit body weight (kcal/g/d). There
are several possible explanations for the discrepancy
between the predicted and inferred values of these
parameters.
First, the assumption that body composition can be
broken down into fat mass and fat-free mass, each with its
own (constant) energy density, may be too simple. This
assumption ignores the presence of non-metabolic body
mass such as extracellular fluid. While models similar to
the one used here have been validated in both mice [32]
and humans [33], these models are validated on the basis of
their ‘‘long-term’’ behavior, so that changes occuring on
faster time scales are not considered. Thus, for instance,
slight changes in hydration that are distinct from changes in
the metabolic components of fat and fat-free mass could
bias the estimates of q and e. It is also not necessary for all
components of fat-free mass (e.g., glycogen vs protein
stores) to change on the same time-scale, and such differ-
ences may be particularly noticeable in short-term studies.
Indeed, in humans, components of body composition have
been observed to change on different time scales [43], and
a similar effect could be occuring here.
A second possibility involves limitations in the energy
expenditure model itself. Numerous metabolic and hor-
monal changes are known to be associated with changes in
energy balance. While the model does include body com-
position and adaptive thermogenesis as components of
energy expenditure, it is possible that the representations of
these quantities are oversimplified.
A third possibility is the existence of biases/tradeoffs
associated with the simultaneous fitting of BW and FI data.
For instance, the model is limited in its ability to describe
fluctuations in food intake that occur with a period of 2–3
days. Yet, any such biases in the estimates of q and e would
have to be quite small given the accuracy of the fits to FI
(over periods greater than 7 days) and BW data (Fig. 1).
Moreover, food intake data was used directly as an input
into the body weight model (as opposed to using the
model-predicted food intake) for the pair-fed group, while
the fits to the body weight data are comparable between the
pair-fed and actively-dosed groups. An alternative
approach is to use the theoretical values of q and e to
simulate the body weight model (using either the model-
predicted food intake or the food intake data directly) and
compare the resulting simulations to the body weight data,
along the lines of a similar analysis in mice [32]. However,
this approach does not accurately recapitulate the observed
BW data for any group (not shown). Because this limitation
applies identically to the pair-fed as well as all actively-
dosed groups, the discrepancies in the parameters q and e
seem to reflect a limitation in the representation of NHP
physiology, and not any effect associated with PF-
05231023.
The energy balance model presented here is developed
from the assumption that each unit of body mass gained or
lost consists of some fixed fraction of fat versus fat-free
mass. Physiologically, the regulation of macronutrient
stores (and thus body composition) is a complex process
depending upon the energy balance of an animal as well as
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many other factors (e.g., hormonal regulation). In male
C57BL/6 mice, body composition has been shown empir-
ically to be described by a time-invariant function which
varies minimally between the animals in an experiment
[31], though the relationship may be sexually dimorphic
[34]. While the animals in the present study are not
genetically identical, this assumption is expected to be
sufficiently accurate for the present purpose (see
Appendix).
A statistically significant correlation structure is
observed in the modeling errors for food intake measure-
ments collected on consecutive days. A similar structure is
observed for measurements separated by 3 or 7 days, but
not two days (Fig. 6 in the Appendix). Because dosing was
administered twice weekly on the first and fourth day of the
week, it seems likely that the observed modeling error is
associated with the shortcomings of the simple K-PD
framework for describing the PF-05231023 mechanism of
action. Conversely, the proposed mathematical model
provides an accurate estimate of the mean food intake over
periods greater than one week. In rodents, PF-05231023
has been proposed to operate at two different time scales as
a result of different rates of clearance of the N- and
C-terminal clippings of the original molecule [26]. The
residual analysis presented here is consistent with a similar
mechanism in NHP; the simple K-PD framework used to
model the onset and washout of treatment accurately
describes the longer-duration mechanism but not the
shorter-duration mechanism. A more mechanistic PKPD
bFig. 1 Model calibration. PF-05231023 is assumed to decrease food
intake as described by the K-PD model (Eqs. (2)–(4)). This decrease
in food intake drives a decrease in body weight according to Eq. (1).
Best-fit model parameters were determined by OLS fit to the available
data (Eq. 8). Model parameters are summarized in Table 3. Left
Calibrated model solution for food intake, in comparison to exper-
imental data. Vertical dashed lines indicate the start and end of the
active-dosing period. Right Calibrated model solution for change in
body weight, in comparison to experimental data. Vertical dashed line
indicates the beginning of the washout period. Data are shown as
mean ± SEM.
























Fig. 2 Statistically significant correlation between residuals at subsequent measurement times for food intake (left p = 4.5 9 10-10) and body
weight (right p = 1.3 9 10-6).






















Initial Body Weight and Food IntakeFig. 3 Relationship between
estimated baseline food intake,
I0, and body weight at t = 0,
BW0. Line of best fit: I0 ¼
166:5BW0  1246 (p = 0.008).
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model of PF-05231023 is complicated both by the complex
dynamics of the molecule [26] as well as the mechanistic
uncertainties surrounding FGF21 itself [9], and such work
is beyond the scope of the current study. Crucially, the
model presented here accurately describes the dose-re-
sponsive change in total food intake associated with PF-
05231023 and supports the hypothesis that PF-05231023
decreases body weight only by its direct effect on food
intake. The K-PD framework used here establishes a basis
for model-based assessment of alternative doses and/or
dose schedules in future studies.
As elsewhere [31, 32, 38, 44, 45], the body weight
model is intended to describe changes in energy balance
and body weight which occur over periods of time greater
than one day. Dynamics which occur at a faster time scale
(e.g., meal patterns within a day) are not represented. As
such, no attempt is made to represent possible pharma-
cotherapeutic actions of PF-05231023 on metabolic end-
points such as plasma insulin and triglycerides, although
such effects have been reported [9, 46]. It has been shown
[38] that the energy balance framework used here is
qualitatively consistent with a hypothetical model of
within-day metabolism which has been averaged over a
longer time period. The actual implementation of such a
within-day model, and a quantitative comparison to the
present results, is an interesting open problem for future
work. Thus, there is significant scope for expansion of the
analysis presented here as additional mechanistic details
become available for PF-05231023 pharmacology and
FGF21 mechanism(s) of action.
Open Access This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creative
commons.org/licenses/by/4.0/), which permits unrestricted use, distri-
bution, and reproduction in anymedium, provided you give appropriate
credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
Appendix: Body weight model derivation
Begin with the basic two-state model [31, 32, 38] which
describes the relationship between fat mass (FM) and fat-












I  Eð Þ:
ð9Þ
Here, FM and FFM represent stores of fat mass and fat-
free mass (both measured in grams), with metabolic den-
sities qFM and qFFM (kcal/g). I and E represent rates of
energy intake and expenditure, both measured in kcal/d.
The function a describes the manner in which body com-




Such a relationship has beendemonstrated empirically inmice
[31, 32] and humans [47]. Energy expenditure is assumed to
vary with body composition and the rate of energy intake,









Here, b (dimensionless) reflects the change in energy
expenditure associated with changes in energy intake (diet-
induced thermogenesis and adaptive thermogenesis; k
(kcal/g/d) is the coefficient of physical activity, cFM and
cFFM are proportionality constants relating basal metabolic













Model Validation, Food Intake: Group6
Model
Data



















Model Validation, Body Weight: Group6
Model
Data
Fig. 4 Assessment of model predictive capacity. Group 6 treatment
protocol was simulated based upon model parameters as estimated
from the calibration data set (Table 3). Baseline food intake was
estimated based upon a linear relationship between I0 and BW0
observed in the calibration data set (Fig. 3) but no additional
parameters were fit to data from Group 6. Left predicted food intake in
comparison to data from Group 6. Vertical dashed lines indicate the
start and end of the active-dosing period. Right predicted change in
body weight in comparison to data from Group 6. Vertical dashed line
indicates the beginning of the washout period. Data are shown as
mean ± SEM.
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rate to FM and FFM, respectively; and gFM and gFFM (kcal/
g) are the metabolic costs of mass deposition for fat mass
and fat-free mass, respectively. All other energy expendi-
ture mechanisms are assumed to be described by the zero-
order term K. This model has been shown to accurately
predict the dynamics of body weight change in mice [32],
and a motivation for the individual terms in Eq. (11) can be
found there. It should be noted that energy expenditure is
modeled to change in response to changes in body weight
and/or food intake, but no changes in energy expenditure
are directly associated with pharmacotherapy.
In the absence of detailed, longitudinal body composi-
tion measurements, the function a is unknown. However,
the function a can be reasonably approximated as a con-
stant, and this approximation greatly simplifies the math-
ematical model. To show this, it is first shown that the
mathematical model is, to first order, robust to the mis-
specification of the function a. (This permits the function a
to be linearized.) Assume the energy partition function can
be written as
aðFM;FFMÞ ¼ a0ðFM;FFMÞ þ a1ðFM;FFMÞ; ð12Þ
for some value of , jj\\1. Then
dFM
dt
¼ I  E
qFM þ qFFMa











where the final approximation follows from Taylor’s








¼ aðI  EÞ
qFM þ qFFMa
¼ a0ðI  EÞ
qFM þ qFFMða0 þ a1Þ
þ a1ðI  EÞ
qFM þ qFFMða0 þ a1Þ






Thus the error resulting from a misspecification of the
energy partition function accumulates at a rate which is no













is valid. It should be noted that the assumption (13) is not
particularly restrictive. Given the values for qFFM , qFM , and
a0 (see next section), the condition (13) is satisified if
a1\1:15. Given the empirical value a0  0:77 (next
section), this means that the permissible (for the approxi-
mation to be valid) error in the function a can even exceed
its nominal value.
Assume then, that a  a0 is constant. At steady state,
I0  E  K þ cFMFM0 þ cFFMFFM0 þ kðFM0 þ FFM0Þ:
ð14Þ
This expression can be solved for K and inserted into the







¼ I  I0ð Þ  b I  I0ð Þ  cFM þ kð Þ FM  FM0ð Þ





















FFM  FFM0  a0 FM  FM0ð Þ:
Combining these expressions,
qFM þ gFM þ a0qFFM þ a0gFFM
1þ a0
 
1 bð Þ I  I0ð Þ
cFM þ a0cFFM
1þ a0 þ k
 
BW  BW0ð Þ:
While this expression involves many unknown parameters,




¼ I  I0ð Þ   BW  BW0ð Þ
where
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1þ a0 þ k
 
: ð16Þ
It should be noted that, while this simplification reduces the
mathematical model to only two unique parameters,
implicit within this model is the energy expenditure model
(11) that describes changes in energy expenditure associ-
ated with changes in body weight or composition. That is,
while PF-05231023 pharmacotherapy is assumed to have a
direct effect only on food intake, this change in food intake
will lead to a change in body weight, which in turn will
lead to changes in energy expenditure..
Finally, it is worth noting that the derivation presented
here relies upon the relationship between I0, K, FM0, and
FFM0 to eliminate the parameter K. An alternative
approach would be to linearize the functions a and E
around a steady state (FM0,FFM0) associated with a rate of
intake I0 [38]. It is trivial to show that the two derivations
are equivalent.
Nominal parameter values
Using Eqs. (15)–(16), theoretical values can be computed
for q and . Based upon prior work [32], qFM ¼ 9:44,
qFFM ¼ 1:80, gFM ¼ 0:18, and gFFM ¼ 0:23. These values
are believed to be common across species. The value of b
has been estimated to range from 0.25 in human infants to
0.40 in rats, and we assume b ¼ 0:25 here. To estimate the
parameters cFM and cFFM , we use Klieber’s Law as in [32].
Assuming cFM ¼ 3:15 kcal/kg/day and cFFM ¼ 21:6 kcal/
kg/day for a 70 kg (lean) human male and a baseline body
weight of 6.5 kg for a (lean) cynomolgus macaque, we
obtain cFM  5:7 kcal/kg/d ¼ 0:0057 kcal/g/d and cFFM 
39:1 kcal/kg/d ¼ 0:0391 kcal/g/d for cynomolgus
macaques.
The parameters k and K must be determined empirically.
To do so, we begin with Eq. (14). A spontaneously obese
cynomolgus macacque (10.6 kg, the mean for all animals in
the current study) consumes approximately 500 kcal/d and
will have a body fat percentage of approximately 30 %
assuming a body condition score of 3.5 [48]. Thus
500 ¼ K þ ð0:0057Þð0:3Þð10600Þ þ ð0:0391Þð0:7Þð10600Þ
þ 10600k:
ð17Þ
Physical activity expenditure (PAE) is defined to be the
difference between total energy expenditure and resting
metabolic rate, PAE ¼ E  RMR ¼ kBW . Also, for less
active animals it is reasonable to assume a physical activity
level (the ratio of total energy expenditure to resting
metabolic rate; PAL ¼ E=RMR) of 1.5 [49]. Thus
kBW0 ¼ E  RMR ¼ ðPAL 1ÞRMR ¼ 0:5RMR:
Using the definition of resting metabolic rate,
RMR ¼ K þ cFMFM þ cFFMFFM,
10600k ¼ 0:5RMR ¼ 0:5 K þ ð0:0057Þð0:3Þð10600Þð
þð0:0391Þð0:7Þð10600ÞÞ:
ð18Þ
Solving the system of Eqs. (17)–(18) for K and k yields
K  25 kcal/d and k  0:0157 kcal/g/d.
The final unknown parameter is the body composition
partition ratio, a. Based upon the data reported in [48] for
male rhesus macaques,
FM ¼ 4:1262þ 0:5658BW
¼ 4:1262þ 0:5658ðFM þ FFMÞ;
and thus
FFM  0:77FM þ 7:3:
Assuming that this cross-sectional relationship is indicative
of the dynamic relationship between FM and FFM, these
data would imply a = 0.77 for rhesus macaques, and we
will use this value for cynomolgus macaques as well.
Inserting all of these values in Eqs. (15)–(16) yields q 
8:4 and   0:05.
Residual plots
Figures 5 and 6.
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Normal Probability Plot, Body Weight
Fig. 5 Residual plots for food intake (left) and body weight.
Residuals do not exhibit any significant structure when viewed as a
function of time (top) or model magnitude (middle), and appear to be
approximately normally distributed (bottom), though there are two
apparent outliers in the BW residuals.
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Fig. 6 Correlation between food intake residuals. Statistically
significant correlation between residuals separated by 1 day
(Fig. 2), 3 days (middle; p = 0.0027), and 7 days (bottom;
p = 8.1 9 10-9), but not 2 days (top; p = 0.065). Similarly, there is
no statistically significant correlation between residuals separated by
4 or 5 days (not shown). This correlation structure is likely the result
of the shortcoming of the K-PD model to describe the multiple time
scales [12] on which PF-05231023 is hypothesized to act.
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